EACS2023: 980 Incidence of non-alcoholic fatty liver disease in antiretroviral therapy-naïve people living with HIV who start a regimen with DTG/ABC/3TC compared to those who start BIC/FTC/TAF at 48-week follow-up at the Hospital de Infectología CMN "La Raza": a preliminary analysis A. Cano-Díaz , E. Pérez-Barragán , S. Triana-González , G.E. Salinas-Velázquez , M.S. Rodríguez-Evaristo , J.A. Mata-Marín , J.E. Gaytán-Martínez Instituto Mexicano del Seguro Social, Ciudad de México, Mexico General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: To determinate the incidence of NAFLD by non-invasive methods in people living with HIV (PLHIV) naïve to antiretroviral therapy (ART) starting with dolutegravir/abacavir/lamivudine (DTG-group) regimen compared with bictegravir/ alafenamide tefonovir/emtricitabine (BIC-group) regimen after 48 weeks of follow-up. Method: A prospective cohort of PLHIV from February 2020 to December 2022 in a reference HIV center was conducted. NAFLD incidence was calculated with TyG, HIS, FLI indexes, hepatic US and elastography at baseline and at 48 weeks between BIC-group and DTG-group. Relative risks for NAFLD were calculated. Results: 86 men PLHIV were included, 46 in BIC-group; median age was 26.0 (IQR 21.7-30.2) and 40 in DTG-group; median age 26 (22.0-30.5). At 48 weeks of ART, TyG in BIC-group was 4.51 (4.36-4.71) vs DTG-group 4.68 (4.44-4.82) (p=0.056), HSI in BIC-group was 30.0 (28.3-33.4) vs DTG-group 31.9 (28.5-35.0) (p=0.18) and FLI in BIC-group was 14.6 (7.41-28.81) vs DTG-group 17.79 (7.8-34.24) (p=0.431). Hepatic steatosis by US at 48 weeks was found in 6 patients (13.0%) in BIC-group and 4 patients (10.0%) in DTG-group (p=0.745); incidence of NAFLD was in 10 patients (10%). Independence risk factor for NAFLD was only HDL-c <40 mg/dL. Conclusions: There was no difference in NAFLD incidence in PLHIV treated with BIC vs DTG. HDL-c <40 mg/dL was a risk factor for NAFLD/NASH development. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 1 1 1 1 1 1 1 186 19TH EUROPEAN AIDS CONFERENCE | WARSAW 2023
RkJQdWJsaXNoZXIy Mzc2ODc=